Jeffrey B. Simon is a commentator and founding partner of SIMON GREENSTONE PANATIER, PC. Ranked as one of the Top 10 Personal Injury Attorney's within America and Co-chair of the National Opioid Litigation Conference, Mr. Simon brings together medical, legal, and law experts to reduce the social and economic harms of the opioid pandemic.
Jeffrey B. Simon announced that he and a committee of trial lawyers, along with the Office of the Texas Attorney General, have reached a historic $1.8 billion settlement for Texas.
A $290 million settlement agreement Tuesday with pharmaceutical giant Johnson & Johnson over what the state claims were deceptive marketing tactics that contributed to the ongoing opioid crisis.
This industrially caused environmental disease will cause enormous harm, both in terms of human suffering...
After a landmark ruling advancing the US asbestos ban, Jeffrey sits down with Linda Reinstein, who co-founded the Asbestos Disease Awareness Organization (ADAO) after losing her husband Alan to mesothelioma in 2006. Linda’s tireless grassroots efforts and public health work have made her a pivotal figure in the fight to ban asbestos and aid those… Continue reading Special Episode: Turning Pain into Purpose: Linda Reinstein’s Asbestos Advocacy Story
Jeffrey B. Simon, trial attorney and author of the book ‘Last Rights: The Fight to Save the Seventh Amendment.’ Discusses the $1.8 billion settlement from Johnson & Johnson related to opioids, and the role of Purdue Pharma and the Sackler family in the opioid epidemic. Diving into the larger issue of the dismantling of the… Continue reading On Air: Why Big Pharma Had To Pay $1.8 Billion
At the start of January, the Food and Drug Administration (FDA) authorized the state of Florida to import prescription drugs from Canada—meaning, for the first time, a state will be able to procure cheaper medications imported from outside the United States. It was a change that advocates have wanted for decades, in the hope it… Continue reading How FDA Ruling Could Unravel Big Pharma’s Stranglehold on US Drugs